Evidence map›Paper›PMID 36145358›Full record

ArticlePharmaceuticals (Basel, Switzerland)2022

Antiproliferative and Apoptotic Effects of Graphene Oxide @AlFu MOF Based Saponin Natural Product on OSCC Line.

Seyyed Mojtaba Mousavi, Seyyed Alireza Hashemi, Yasmin Ghahramani, Rouhollah Azhdari, Khadijeh Yousefi, Ahmad Gholami, Fatemeh Fallahi Nezhad, Neralla Vijayakameswara Rao, Navid Omidifar, Wei-Hung Chiang

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 28 citations in OpenAlex.

  1. Innovative nanoparticle strategies for treating oral cancers.Medical oncology (Northwood, London, England) · 2025
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Seyyed Mojtaba MousaviDepartment of Chemical Engineering, National Taiwan University of Science and Technology, Taipei City 106335, Taiwan.ORCID 0000-0003-2866-9286
Seyyed Alireza HashemiNanomaterials and Polymer Nanocomposites Laboratory, School of Engineering, University of British Columbia, Kelowna, BC V1V 1V7, Canada.
Yasmin GhahramaniDepartment of Endodontics, Shiraz University of Medical Sciences, Shiraz 71956-15787, Iran.
Rouhollah AzhdariBiotechnology Research Center, Shiraz University of Medical Sciences, Shiraz 71468-64685, Iran.
Khadijeh YousefiDepartment of Dental Materials and Biomaterials Research Centre, Shiraz Dental School, Shiraz University of Medical Sciences, Shiraz 71956-15787, Iran.
Ahmad GholamiBiotechnology Research Center, Shiraz University of Medical Sciences, Shiraz 71468-64685, Iran.ORCID 0000-0003-1851-159X
Fatemeh Fallahi NezhadBiotechnology Research Center, Shiraz University of Medical Sciences, Shiraz 71468-64685, Iran.
Neralla Vijayakameswara RaoDepartment of Chemical Engineering, National Taiwan University of Science and Technology, Taipei City 106335, Taiwan.ORCID 0000-0001-8534-7158
Navid OmidifarDepartment of Pathology, Shiraz University of Medical Sciences, Shiraz 71468-64685, Iran.
Wei-Hung ChiangDepartment of Chemical Engineering, National Taiwan University of Science and Technology, Taipei City 106335, Taiwan.ORCID 0000-0002-6350-6696
Shiraz University of Medical Sciences · IRNational Taiwan University of Science and Technology · TWUniversity of British Columbia · CA

Funding

Ministry of Science and Technology grant number: MOST 110-2628-E-011-003, MOST 109-2923-E-011-003-MY, MOST 111-NU-E-011-001-NU
6 · The paper itself

Abstract

The increasing rate of oral squamous cell carcinoma (OSCC) and the undesirable side effects of anticancer agents have enhanced the demand for the development of efficient, detectable, and targeted anticancer systems. Saponins are a diverse family of natural glycosides that have recently been evaluated as an effective compound for the targeted therapy of squamous cell carcinoma. Due to their porous nature and stable structure, metal-organic frameworks (MOFs) are a well-known substance form for various biological applications, such as drug delivery. In this study, we fabricated a novel hybrid, highly porous and low-toxic saponin-loaded nanostructure by modifying graphene oxide (GO)/reduced GO (rGO) with aluminum fumarate (AlFu) as MOF core-shell nanocomposite. The characterization of the nanostructures was investigated by FTIR, TEM, EDX, FESEM, and BET. MTT assay was used to investigate the anticancer activity of these compounds on OSCC and PDL normal dental cells. The effect of the nanocomposites on OSCC was then investigated by studying apoptosis and necrosis using flow cytometry. The GO/rGO was decorated with a saponin-AlFu mixture to further investigate cytotoxicity. The results of the MTT assay showed that PDL cells treated with AlFu-GO-saponin at a concentration of 250 μg/mL had a viability of 74.46 ± 16.02%, while OSCC cells treated with this sample at a similar concentration had a viability of only 38.35 ± 19.9%. The anticancer effect of this nanostructure on OSCC was clearly demonstrated. Moreover, the number of apoptotic cells in the AlFu-GO-saponin and AlFu-rGO-saponin groups was 10.98 ± 2.36%-26.90 ± 3.24% and 15.9 ± 4.08%-29.88 ± 0.41%, respectively, compared with 2.52 ± 0.78%-1.31 ± 0.62% in the untreated group. This significant increase in apoptotic effect observed with AlFu-rGO-saponin was also reflected in the significant anticancer effect of saponin-loaded nanostructures. Therefore, this study suggests that an effective saponin delivery system protocol for the precise design and fabrication of anticancer nanostructures for OSCC therapy should be performed prior to in vivo evaluations.

Indexed as

aluminum fumarategraphene oxidesaponinsquamous cell carcinoma cancer

Identifiers

PMID36145358
PMCPMC9504826
OpenAlexW4296005403

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.